Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18997378 | 0.81 | TLR7 (0.72) | RAB9ATLR7ALDH1A1HPGDLMNA | |
| SCHEMBL18997390 | 0.78 | TLR7 (0.72) | RAB9ASMN1; SMN2KMT2ANPC1ADORA2A | |
| SCHEMBL4767995 | 0.75 | ALDH1A1 (0.56) | ALDH1A1 | |
| SCHEMBL14028264 | 0.73 | HDAC1 (0.41) | SMN1; SMN2KMT2ATLR7ALDH1A1HPGD | |
| SCHEMBL8722201 | 0.72 | SMN1; SMN2 (0.69) | RAB9ASMN1; SMN2MAPK1KMT2ANPC1 | |
| SCHEMBL24499085 | 0.71 | HPGD (0.53) | RAB9ASMN1; SMN2MAPK1KMT2ANPC1 | |
| SCHEMBL18781728 | 0.70 | SLC40A1 (0.60) | RAB9ASMN1; SMN2MAPK1KMT2ANPC1 | |
| SCHEMBL29505832 | 0.70 | SLC40A1 (0.51) | RAB9ANPC1TLR7CYP1A2CYP3A4 | |
| SCHEMBL28721377 | 0.70 | SLC40A1 (0.51) | RAB9ANPC1TLR7CYP1A2CYP3A4 | |
| SCHEMBL14368134 | 0.70 | HPGD (0.54) | RAB9ASMN1; SMN2NPC1TLR7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446120-B2 | Peptidomimetic modulators of cell adhesion | ADHEREX TECHNOLOGIES, INC. (CA) | 2008-11-04 | — | — | US | disclosed |
| US-20080081831-A1 | PEPTIDOMIMETIC MODULATORS OF CELL ADHESION | ADHEREX TECHNOLOGIES, INC. (CA) | 2008-04-03 | — | — | US | disclosed |
| US-7268115-B2 | Cyclic peptides; three-dimensional structures; screening; anticancer agents; angiogenesis inhibitors; drug delivery | ADHEREX TECHNOLOGIES, INC. (CA) | 2007-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081831-A1 | PEPTIDOMIMETIC MODULATORS OF CELL ADHESION | CDH1, EPCAM, VCAM1 | RAB9A 2023/4885SMN1; SMN2 4365/4885MAPK1 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.